Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

411P - Laparoscopic versus open liver resection for colorectal cancer liver metastases: Five-year actual survival of the previously reported randomized controlled trial – The OSLO-COMET Trial

Date

10 Sep 2022

Session

Poster session 08

Topics

Clinical Research;  Surgical Oncology

Tumour Site

Hepatobiliary Cancers;  Colon and Rectal Cancer

Presenters

Davit Aghayan

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

D. Aghayan1, Å. Fretland2, A. Kazaryan3, V. Dagenborg4, M. Fagerland5, K. Flatmark4, B. Edwin1

Author affiliations

  • 1 The Intervention Centre, Oslo University Hospital - Rikshospitalet, 0424 - Oslo/NO
  • 2 Department Of Hpb Surgery, Oslo University Hospital - Rikshospitalet, 0424 - Oslo/NO
  • 3 Department Of Gastrointestinal Surgery, Sykehuset Ostfold Kalnes, 1714 - Gralum/NO
  • 4 Department Of Tumour Biology, Oslo University Hospital - Radiumhospitalet, 0424 - Oslo/NO
  • 5 Oslo Centre For Biostatistics And Epidemiology, Research Support Service, Oslo University Hospital - Rikshospitalet, 0424 - Oslo/NO

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 411P

Background

Research on laparoscopic liver resection has shown shorter recovery time, a better quality of life, and fewer postoperative complications. Our previous report of the OSLO-COMET trial showed that laparoscopic surgery in patients with colorectal cancer liver metastases was equivalent to open resection regarding oncologic outcomes. The current report aimed to investigate the survival outcomes of this trial after a minimum follow-up of 6 years.

Methods

Patients with resectable colorectal liver metastases from February 2012 to January 2016 were randomized between laparoscopic and open parenchyma-sparing liver resection with curative intent (ClinicalTrials.gov: NCT01516710). The trial's primary outcome was postoperative morbidity within 30 days, while overall survival was a predefined secondary endpoint. Patients received perioperative chemotherapy following Norwegian guidelines, at the discretion of the multidisciplinary team.

Results

Two hundred eighty patients were randomized to laparoscopic (n = 133) or open (n = 147) surgery. Current survival analysis was performed on January 20, 2022, with a minimum of 72 months follow-up and with a median follow-up of 94 months (95%CI, 91 to 97). Median overall survival was 71 months (95% CI 47 to 95) in the laparoscopic surgery group and 74 months (95%CI, 52 to 96) in the open surgery group (p=0.970), and the 5-year actual survival compiled 55% and 54%, respectively (HR 1.006 [0.738 to 1.372]). Median recurrence-free survival (RFS) was 17 months (95%CI, 10 to 23) after laparoscopy and 16 months (95%CI, 8 to 24) after open surgery, with a 5-year RFS of 33% and 31% (p = 0.705).

Conclusions

These long-term outcomes after a minimum follow-up of six years, together with short-term results, further support the use of laparoscopic surgery to treat colorectal cancer liver metastases.

Clinical trial identification

NCT01516710.

Editorial acknowledgement

Legal entity responsible for the study

The OSLO-COMET Survival Study Collaborators.

Funding

South-Eastern Norway Regional Health Authority.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.